CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Han, Jianfeng ^a,b   Chu, Jianhong ^b   Keung Chan, Wing ^b   Zhang, Jianying ^c   Wang, Youwei ^b   Cohen, Justus B ^d   Victor, Aaron ^b   Meisen, Walter H ^c   Kim, Sung Hak ^c   Grandi, Paola ^d   Wang, Qi En ^a   He, Xiaoming ^e   Nakano, Ichiro ^c   Chiocca, E Antonio ^f   Glorioso Iii, Joseph C ^d   Kaur, Balveen ^c   Caligiuri, Michael A ^a,b   Yu, Jianhua ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e Ohio State University   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; GAMMA INTERFERON; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL; BIOSYNTHESIS; CANCER STEM CELL; CELL MOTION; CYTOTOXICITY; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION; GENETICS; GLIOBLASTOMA; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; NATURAL KILLER CELL; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MICE; NEOPLASTIC STEM CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937010762     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11483     Document Type: Article

References (36)

1. Morgan, R. A. et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Human gene therapy 23, 1043-1053 (2012).
2. Imperato, J. P., Paleologos, N. A. & Vick, N. A. Effects of treatment on long-term survivors with malignant astrocytomas. Annals of neurology 28, 818-822 (1990).
3. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480-489 (2011).
4. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
5. Salomon, D. S., Brandt, R., Ciardiello, F. & Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Critical reviews in oncology/hematology 19, 183-232 (1995).
6. Zandi, R., Larsen, A. B., Andersen, P., Stockhausen, M. T. & Poulsen, H. S. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cellular signalling 19, 2013-2023 (2007).
7. Aldape, K. D. et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. Journal of neuropathology and experimental neurology 63, 700-707 (2004).
8. Biernat, W., Huang, H., Yokoo, H., Kleihues, P. & Ohgaki, H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain pathology 14, 131-136 (2004).
9. Fan, Q. W. et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer cell 24, 438-449 (2013).
10. Sugawa, N., Ekstrand, A. J., James, C. D. & Collins, V. P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proceedings of the National Academy of Sciences of the United States of America 87, 8602-8606 (1990).
11. Ohno, M. et al. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer science 101, 2518-2524 (2010).
12. Sampson, J. H. et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 20, 972-984 (2014).
13. Tonn, T. et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15, 1563-1570 (2013).
14. Arai, S. et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 10, 625-632 (2008).
15. Tonn, T., Becker, S., Esser, R., Schwabe, D. & Seifried, E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. Journal of hematotherapy & stem cell research 10, 535-544 (2001).
16. Mao, P. et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proceedings of the National Academy of Sciences of the United States of America 110, 8644-8649 (2013).
17. Papapetrou, E. P. et al. Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. Nature biotechnology 29, 73-78 (2011).
18. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England journal of medicine 365, 725-733 (2011).
19. Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. The New England journal of medicine 368, 1509-1518 (2013).
20. Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Science translational medicine 5, 177ra138 (2013).
21. Ahmed, N. et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 16, 474-485 (2010).
22. Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular therapy : the journal of the American Society of Gene Therapy 18, 843-851 (2010).
23. Esser, R. et al. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. Journal of cellular and molecular medicine 16, 569-581 (2012).
24. Chu, J. et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28, 917-927 (2014).
25. Chandramohan, V. et al. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 19, 4717-4727 (2013).
26. Uherek, C. et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100, 1265-1273 (2002).
27. Schonfeld, K. et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Molecular therapy : the journal of the American Society of Gene Therapy 23, 330-338 (2015).
28. Jordan, C. T. Cancer stem cells: controversial or just misunderstood? Cell Stem Cell 4, 203-205 (2009).
29. Brennan, C. et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PloS one 4, e7752 (2009).
30. Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer cell 9, 157-173 (2006).
31. Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 17, 98-110 (2010).
32. Hayashi, H. et al. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer immunology, immunotherapy : CII 53, 497-509 (2004).
33. Humphrey, P. A. et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proceedings of the National Academy of Sciences of the United States of America 87, 4207-4211 (1990).
34. Pule, M. A. et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 12, 933-941 (2005).
35. Yu, J. et al. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 115, 274-281 (2010).
36. He, S. et al. MicroRNAs activate natural killer cells through Toll-like receptor signaling. Blood 121, 4663-4671 (2013).